iA Global Asset Management Inc. Acquires 200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

iA Global Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the third quarter, HoldingsChannel reports. The firm owned 13,186 shares of the biopharmaceutical company’s stock after purchasing an additional 200 shares during the quarter. iA Global Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $13,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Czech National Bank grew its stake in shares of Regeneron Pharmaceuticals by 8.7% in the second quarter. Czech National Bank now owns 20,212 shares of the biopharmaceutical company’s stock valued at $21,243,000 after acquiring an additional 1,624 shares in the last quarter. Gibson Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $284,000. Transform Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.9% in the second quarter. Transform Wealth LLC now owns 9,052 shares of the biopharmaceutical company’s stock valued at $9,514,000 after buying an additional 258 shares during the period. Sequoia Financial Advisors LLC grew its position in Regeneron Pharmaceuticals by 5.0% during the second quarter. Sequoia Financial Advisors LLC now owns 1,522 shares of the biopharmaceutical company’s stock worth $1,600,000 after buying an additional 73 shares in the last quarter. Finally, Cooper Financial Group bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $293,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Finally, Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Stock Up 1.3 %

REGN stock opened at $778.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The stock’s 50 day simple moving average is $882.14 and its 200 day simple moving average is $1,013.01. The company has a market cap of $85.49 billion, a P/E ratio of 19.25, a price-to-earnings-growth ratio of 2.91 and a beta of 0.08.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.